GlaxoSmithKline hands rare disease drug back to partner Amicus
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline gave back the rights to develop and market an experimental treatment for the rare genetic disorder Fabry disease to partner Amicus Therapeutics.
You may also be interested in...
Amicus' Oral Fabry Drug Priced To Compete Against Traditional ERT
FDA approved Galafold under accelerated approval, paving the way for the launch of the first oral therapy to treat a subset of patients with the rare condition Fabry disease. Amicus priced Galafold at $315,000 per year.
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.